Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cronos Group (CRON – Research Report), Travere Therapeutics (TVTX – Research Report) and Ascendis Pharma (ASND – Research Report).
Cronos Group (CRON)
Bank of America Securities analyst Lisa Lewandowski reiterated a Sell rating on Cronos Group yesterday and set a price target of $1.55. The company’s shares closed last Wednesday at $1.75, close to its 52-week low of $1.67.
Lewandowski has an average return of
According to TipRanks.com, Lewandowski is ranked #1222 out of 8379 analysts.
Currently, the analyst consensus on Cronos Group is a Hold with an average price target of $2.53.
See today’s best-performing stocks on TipRanks >>
Travere Therapeutics (TVTX)
Bank of America Securities analyst Greg Harrison maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $39.00. The company’s shares closed last Wednesday at $17.89.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $28.62 average price target, which is a 73.6% upside from current levels. In a report issued on May 22, TD Cowen also initiated coverage with a Buy rating on the stock with a $30.00 price target.
Ascendis Pharma (ASND)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ascendis Pharma, with a price target of $107.00. The company’s shares closed last Wednesday at $86.97.
According to TipRanks.com, Ahmad is a 5-star analyst with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $135.50, representing a 58.2% upside. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRON:
- Cronos Group Announces Streamlined Operating Structure to Improve Cash Flow
- Cronos Group Inc. to Speak at Bernstein’s 39th Annual Strategic Decisions Conference
- Taxes Prove Problematic for Canadian Cannabis Companies
- Rising High: Exclusive talk with financial services firm Safe Harbor
- Rising High: Exclusive talk with investment management firm Poseidon
